• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型氟喹诺酮类药物。

The newer fluoroquinolones.

机构信息

Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 900, Chicago, IL 60611, USA.

出版信息

Med Clin North Am. 2011 Jul;95(4):793-817, viii. doi: 10.1016/j.mcna.2011.03.006.

DOI:10.1016/j.mcna.2011.03.006
PMID:21679792
Abstract

Clinicians have enthusiastically used fluoroquinolones owing to their good safety profile and wide range of indications. This article reviews fluoroquinolone pharmacology, pharmacodynamic principles, and fluoroquinolone resistance mechanisms, highlighting recent trends in the epidemiology of fluoroquinolone resistance among gram-negative organisms and Streptococcus pneumonia. Important fluoroquinolone safety concerns are discussed, along with indications for the most commonly used fluoroquinolones--ciprofloxacin, levofloxacin, and moxifloxacin.

摘要

临床医生因其良好的安全性和广泛的适应证而热衷于使用氟喹诺酮类药物。本文综述了氟喹诺酮类药物的药理学、药效学原则和氟喹诺酮类耐药机制,重点介绍了近年来革兰氏阴性菌和肺炎链球菌中氟喹诺酮类耐药的流行病学趋势。本文还讨论了氟喹诺酮类药物的重要安全性问题,并介绍了最常用的氟喹诺酮类药物——环丙沙星、左氧氟沙星和莫西沙星的适应证。

相似文献

1
The newer fluoroquinolones.新型氟喹诺酮类药物。
Med Clin North Am. 2011 Jul;95(4):793-817, viii. doi: 10.1016/j.mcna.2011.03.006.
2
The newer fluoroquinolones.新型氟喹诺酮类药物。
Infect Dis Clin North Am. 2009 Dec;23(4):1027-51, x. doi: 10.1016/j.idc.2009.06.003.
3
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.化脓性链球菌emm6型中高水平氟喹诺酮耐药性的出现以及环丙沙星、左氧氟沙星和莫西沙星的体外耐药性选择。
J Antimicrob Chemother. 2009 May;63(5):886-94. doi: 10.1093/jac/dkp057. Epub 2009 Mar 11.
4
Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.氟喹诺酮类药物对金黄色葡萄球菌高水平耐苯唑西林的二项选择。
Int J Antimicrob Agents. 2010 Sep;36(3):216-21. doi: 10.1016/j.ijantimicag.2010.04.014. Epub 2010 Jul 14.
5
The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.莫西沙星及其他氟喹诺酮类药物在特殊患者群体中的安全性概况。
Curr Med Res Opin. 2007 Jun;23(6):1403-13. doi: 10.1185/030079907X188099. Epub 2007 May 8.
6
Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.铜绿假单胞菌引起医院感染的氟喹诺酮类耐药与左氧氟沙星而非环丙沙星的使用相关。
Int J Antimicrob Agents. 2010 Mar;35(3):261-4. doi: 10.1016/j.ijantimicag.2009.11.007. Epub 2009 Dec 31.
7
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.体外感染模型,用于表征外排泵抑制对预防肺炎链球菌对左氧氟沙星和环丙沙星耐药性的影响。
Antimicrob Agents Chemother. 2007 Nov;51(11):3988-4000. doi: 10.1128/AAC.00391-07. Epub 2007 Sep 10.
8
Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.1995 - 1999年美国肺炎链球菌对氟喹诺酮类药物的耐药性
MMWR Morb Mortal Wkly Rep. 2001 Sep 21;50(37):800-4.
9
Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).北美和欧洲分离出的耐氟喹诺酮β溶血性链球菌属的特征,包括耐氟喹诺酮解没食子酸链球菌亚种似马链球菌的首次报告:哨兵抗菌监测计划(1997 - 2004年)报告
Diagn Microbiol Infect Dis. 2006 Jun;55(2):119-27. doi: 10.1016/j.diagmicrobio.2005.12.006. Epub 2006 Mar 10.
10
Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage.尽管氟喹诺酮类药物的使用量很高,但社区获得性肺炎患者的肺炎链球菌中氟喹诺酮耐药株和耐药前体株的流行率较低。
Int J Med Microbiol. 2011 Jan;301(1):53-7. doi: 10.1016/j.ijmm.2010.05.004. Epub 2010 Aug 7.

引用本文的文献

1
Comparative genomics of quinolone-resistant Escherichia coli from broilers and humans in Norway.挪威肉鸡和人类中喹诺酮类耐药大肠杆菌的比较基因组学研究。
BMC Microbiol. 2024 Jul 6;24(1):248. doi: 10.1186/s12866-024-03412-3.
2
Assessment of the impact of intravenous antibiotics treatment on gut microbiota in patients: Clinical data from pre-and post-cardiac surgery.评估静脉用抗生素治疗对心脏手术前后患者肠道微生物群的影响:临床数据。
Front Cell Infect Microbiol. 2023 Jan 19;12:1043971. doi: 10.3389/fcimb.2022.1043971. eCollection 2022.
3
Molecular characteristics of fluoroquinolone-resistant Escherichia coli isolated from suckling piglets with colibacillosis.
氟喹诺酮类耐药大肠杆菌的分子特征从仔猪大肠杆菌病分离。
BMC Microbiol. 2022 Sep 15;22(1):216. doi: 10.1186/s12866-022-02632-9.
4
Systemic quinolones and risk of retinal detachment III: a nested case-control study using a US electronic health records database.全身用喹诺酮类药物与视网膜脱离风险 III:一项使用美国电子健康记录数据库的巢式病例对照研究。
Eur J Clin Pharmacol. 2022 Jun;78(6):1019-1028. doi: 10.1007/s00228-021-03260-4. Epub 2022 Mar 15.
5
Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system.全身性喹诺酮类药物与急性肝衰竭风险I:来自美国食品药品监督管理局不良事件报告系统的数据分析
JGH Open. 2021 Jun 4;5(7):778-784. doi: 10.1002/jgh3.12585. eCollection 2021 Jul.
6
Thiosemicarbazide Derivatives Decrease the ATPase Activity of Topoisomerase IV, Inhibit Mycobacterial Growth, and Affect Replication in .硫代卡巴肼衍生物降低拓扑异构酶 IV 的 ATP 酶活性,抑制分枝杆菌生长,并影响. 的复制。
Int J Mol Sci. 2021 Apr 9;22(8):3881. doi: 10.3390/ijms22083881.
7
Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.系统喹诺酮类药物与急性肝衰竭风险 III:一项使用美国电子健康记录数据库的巢式病例对照研究。
J Gastroenterol Hepatol. 2021 Aug;36(8):2307-2314. doi: 10.1111/jgh.15504. Epub 2021 Mar 31.
8
An sRNA Screen for Reversal of Quinolone Resistance in .一种用于逆转. 中喹诺酮类耐药性的 sRNA 筛选
G3 (Bethesda). 2020 Jan 7;10(1):79-88. doi: 10.1534/g3.119.400199.
9
Dual Glycation-Inflammation Modulation, DPP-IV and Pancraetic Lipase Inhibitory Potentials and Antiproliferative Activity of Novel Fluoroquinolones.新型氟喹诺酮类药物的双重糖基化-炎症调节、二肽基肽酶-IV及胰脂肪酶抑制潜力和抗增殖活性
Asian Pac J Cancer Prev. 2019 Aug 1;20(8):2503-2514. doi: 10.31557/APJCP.2019.20.8.2503.
10
Successful Use of Octreotide Therapy for Refractory Levofloxacin-Induced Hypoglycemia: A Case Report and Literature Review.奥曲肽治疗难治性左氧氟沙星诱导的低血糖症的成功应用:一例报告及文献综述
Case Rep Crit Care. 2019 May 9;2019:3560608. doi: 10.1155/2019/3560608. eCollection 2019.